Tianjin Development Holdings (HK:0882) has released an update.
Tianjin Lisheng Pharmaceutical, a subsidiary of Tianjin Development Holdings, reported a significant decrease in net profit for the first nine months of 2024, from RMB 342.67 million last year to RMB 168.33 million. Despite a rise in operating income to over RMB 1 billion, increased costs and expenses have impacted profitability. Investors may find these financial trends noteworthy as the company navigates a challenging market environment.
For further insights into HK:0882 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
